Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
about
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Evolutionary biology of high-risk multiple myeloma.Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
P2860
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bi-allelic inactivation is mor ...... independent prognostic marker.
@en
Bi-allelic inactivation is mor ...... independent prognostic marker.
@nl
type
label
Bi-allelic inactivation is mor ...... independent prognostic marker.
@en
Bi-allelic inactivation is mor ...... independent prognostic marker.
@nl
prefLabel
Bi-allelic inactivation is mor ...... independent prognostic marker.
@en
Bi-allelic inactivation is mor ...... independent prognostic marker.
@nl
P2093
P2860
P50
P356
P1433
P1476
Bi-allelic inactivation is mor ...... independent prognostic marker.
@en
P2093
B Barlogie
E Peterson
F van Rhee
P2860
P2888
P356
10.1038/BCJ.2017.12
P577
2017-02-24T00:00:00Z